OBJECTIVE: To assess long-term efficacy and safety of salsalate to improve glycemia in persons with diabetes risk, who are overweight with statin-treated, stable coronary heart disease. METHODS:Glycemic status was assessed in 192 persons without diabetes at baseline in a pre-specified secondary analysis from Targeting INflammation Using SALsalate in CardioVascular Disease (TINSAL-CVD), a multi-center, double-masked, randomized (1:1), placebo-controlled, parallel clinical trial. RESULTS:Participants were mostly Caucasian males, age 60±7 years, BMI 31.4±3.0 kg/m2 , fasting glucose 92.8±11.0 mg/dL, and HbA1c 5.8±0.3%. Reductions in mean fasting glucose -5.70 mg/dL (95%CI: -7.44 to -3.97 mg/dL, P<0.001), HbA1c -0.11% (95%CI: -0.210 to -0.002%, P=0.046) and glycated serum protein -81.8 μg/mL (95%CI: -93.7 to -69.9 μg/mL, P<0.001) were demonstrated in salsalate compared to placebo-assigned groups over 30 months. Reductions in fasting glucose and glycated serum protein were greater with salsalate compared to placebo in participants with prediabetes compared to a normoglycemic sub-group (Pinteraction =0.018). Salsalate lowered total white blood cell counts (mean difference -0.7x103 /μL, 95%CI: -1.0 to -0.4 x103 /μL, P<0.001) and increased adiponectin (mean difference 1.8 μg/mL, 95%CI: 0.9 to 2.6 μg/mL, P<0.001) and albuminurea (16.7 μg/mg, 95%CI: 6.4 to 27.1 μg/mg, P<0.001) compared to placebo, consistent with previous results for patients with type 2 diabetes taking salsalate for shorter times. CONCLUSIONS: Salsalate improves glycemia in obese persons at increased risk for diabetes, and hence may decrease risk of incident type 2 diabetes. Salsalate may inform new therapeutic approaches for diabetes prevention, but renal safety may limit clinical utility.
RCT Entities:
OBJECTIVE: To assess long-term efficacy and safety of salsalate to improve glycemia in persons with diabetes risk, who are overweight with statin-treated, stable coronary heart disease. METHODS: Glycemic status was assessed in 192 persons without diabetes at baseline in a pre-specified secondary analysis from Targeting INflammation Using SALsalate in CardioVascular Disease (TINSAL-CVD), a multi-center, double-masked, randomized (1:1), placebo-controlled, parallel clinical trial. RESULTS:Participants were mostly Caucasian males, age 60±7 years, BMI 31.4±3.0 kg/m2 , fasting glucose 92.8±11.0 mg/dL, and HbA1c 5.8±0.3%. Reductions in mean fasting glucose -5.70 mg/dL (95%CI: -7.44 to -3.97 mg/dL, P<0.001), HbA1c -0.11% (95%CI: -0.210 to -0.002%, P=0.046) and glycated serum protein -81.8 μg/mL (95%CI: -93.7 to -69.9 μg/mL, P<0.001) were demonstrated in salsalate compared to placebo-assigned groups over 30 months. Reductions in fasting glucose and glycated serum protein were greater with salsalate compared to placebo in participants with prediabetes compared to a normoglycemic sub-group (Pinteraction =0.018). Salsalate lowered total white blood cell counts (mean difference -0.7x103 /μL, 95%CI: -1.0 to -0.4 x103 /μL, P<0.001) and increased adiponectin (mean difference 1.8 μg/mL, 95%CI: 0.9 to 2.6 μg/mL, P<0.001) and albuminurea (16.7 μg/mg, 95%CI: 6.4 to 27.1 μg/mg, P<0.001) compared to placebo, consistent with previous results for patients with type 2 diabetes taking salsalate for shorter times. CONCLUSIONS:Salsalate improves glycemia in obesepersons at increased risk for diabetes, and hence may decrease risk of incident type 2 diabetes. Salsalate may inform new therapeutic approaches for diabetes prevention, but renal safety may limit clinical utility.
Authors: Thomas H Hauser; Ninad Salastekar; Ernst J Schaefer; Tanvi Desai; Harvey L Goldfine; Kristen M Fowler; Griffin M Weber; Francine Welty; Melvin Clouse; Steven E Shoelson; Allison B Goldfine Journal: JAMA Cardiol Date: 2016-07-01 Impact factor: 14.676
Authors: Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle Journal: Lancet Date: 2012-06-28 Impact factor: 79.321
Authors: Allison B Goldfine; Vivian Fonseca; Kathleen A Jablonski; Yii-Der Ida Chen; Laura Tipton; Myrlene A Staten; Steven E Shoelson Journal: Ann Intern Med Date: 2013-07-02 Impact factor: 25.391
Authors: Arben Cuadari; Federica Pollastro; Juan D Unciti-Broceta; Diego Caprioglio; Alberto Minassi; Annalisa Lopatriello; Eduardo Muñoz; Orazio Taglialatela-Scafati; Giovanni Appendino Journal: Acta Pharm Sin B Date: 2019-06-24 Impact factor: 11.413
Authors: Naureen Javeed; Tracy K Her; Matthew R Brown; Patrick Vanderboom; Kuntol Rakshit; Aoife M Egan; Adrian Vella; Ian Lanza; Aleksey V Matveyenko Journal: Cell Rep Date: 2021-08-24 Impact factor: 9.423